A. Kapp

发表

CHIRALITY VS. HOMFLY AND KAUFFMAN POLYNOMIALS

Sandy Ganzell, A. Kapp, 2008 .

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Robert W. Hsieh, Melissa L. Johnson, L. Paz-Ares, 2020 .

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

I. Flinn, A. Ashkenazi, C. Cheah, 2015, The Lancet. Haematology.

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2013, Clinical colorectal cancer.

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

J. Baselga, D. Patt, S. Isakoff, 2018, Clinical Trials.

Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial

R. Sudlow, P. Leszczyński, J. Schechtman, 2011 .

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

M. Espié, Sung-Bae Kim, J. Baselga, 2017, The Lancet. Oncology.

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

D. Schadendorf, N. Aaronson, M. Muller, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

A. Jimeno, M. Hidalgo, J. Baselga, 2015, Clinical Cancer Research.

Are clusters found in one dataset present in another dataset?

Amy V Kapp, Robert Tibshirani, R. Tibshirani, 2007, Biostatistics.

Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.

Amy V Kapp, Yasodha Natkunam, Robert J. Marinelli, 2007, The American journal of pathology.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

A. Jimeno, J. Machiels, T. Seiwert, 2016, Cancer.

Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

J. Bendell, A. Ashkenazi, M. Kozloff, 2012 .

Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2011 .

Discovery and validation of breast cancer subtypes

Amy V Kapp, Robert Tibshirani, Wonshik Han, 2006, BMC Genomics.

986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT).

A. Jimeno, P. Harari, C. Nutting, 2014, Annals of Oncology.

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients withPIK3CA-mutant HR+/HER2- breast cancer

K. Hutchinson, D. Juric, A. Italiano, 2020 .

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

A. Jimeno, P. Harari, C. Nutting, 2016, Front. Oncol..

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

M. Hidalgo, J. Tabernero, V. Ganju, 2018, Clinical Cancer Research.

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.

J. Baselga, D. Patt, S. Isakoff, 2015 .

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

M. Espié, Sung-Bae Kim, J. Baselga, 2018 .

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

I. Flinn, A. Ashkenazi, C. Cheah, 2015, The Lancet. Haematology.

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

J. Berlin, M. Hidalgo, P. LoRusso, 2017, The oncologist.

Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

M. Hidalgo, J. Tabernero, V. Ganju, 2015 .